A phase I/Ib, open label study of LSZ102 single agent and LSZ102 in combination with eitherLEE011 (LSZ102 + LEE011) or BYL719 (LSZ102 + BYL719) in patients with advanced or metastatic ER+ breast cancer who have progressed after endocrine therapy.
Research Grant
Administered By
Duke Cancer Institute
Awarded By
Novartis Pharmaceuticals Corporation
Start Date
June 1, 2016
End Date
November 23, 2022
Administered By
Duke Cancer Institute
Awarded By
Novartis Pharmaceuticals Corporation
Start Date
June 1, 2016
End Date
November 23, 2022